AMENDED CLAIMS

1. (original) A lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula
X-Y-Z-
wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO_2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula
-$[C(O)]_m$PHG
wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

2. (original) A compound according to claim 1 wherein each non-polar moiety is of the formula X-Y-Z- wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO_2, SO, and O, and Z is an optional hydrocarbyl group,

3. (currently amended) A compound according to claim 1 wherein the compound is of the formula



wherein p is from 1 to 10, ~~preferably 1, 2 or 3,~~ and wherein each X, Y and Z is selected independently of each other.

4. (original) A compound according to claim 1 wherein the compound is of the formula



5. (original) A compound according to claim 1 comprising at least two non-polar moieties wherein each is independently selected from non-polar moieties of the formula X-Y-Z-.

6. (original) A compound according to claim 3 wherein the compound is of the formula



wherein each X, Y and Z is selected independently of each other.

7. (original) A compound according to claim 5 wherein the compound is of the formula



wherein each X, Y and Z is selected independently of each other.

8. (currently amended) A compound according ~~to any one of the preceding claims~~ claim 1 wherein the polar head group is derived from one of phospholipids, ceramides, triacylglycerols, lysophospholipids, phosphatidylserines, glycerols, alcohols, alkoxy compounds, monoacylglycerols, gangliosides, sphingomyelins, cerebrosides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols (PI), diacylglycerols, p~~P~~hosphatidic acids, glycerocarbohydrates, polyalcohols and phosphatidylglycerols.

9. (original) A compound according to claim 8 wherein the polar head group is derived from a phospholipid.

10. (original) A compound according to claim 9 wherein the phospholipid is a neutral or anionic phospholipid.

11. (original) A compound according to claim 10 wherein the phospholipid is selected from phosphatidylcholine (PC) and phosphatidylethanolamine (PE).

12. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein the polar head group (PHG) is of the formula -W-Linker-HG, wherein W is selected from CH_2, O, NR^1 and S, wherein R^1 is H or a hydrocarbyl group, wherein Linker is an optional linker group, and HG is a head group.

13. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl.

14. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from unsubstituted alkyl, unsubstituted alkenyl and unsubstituted alkynyl.

15. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from unsubstituted C_6-C_{24} alkyl, unsubstituted C_6-C_{24} alkenyl and unsubstituted C_6-C_{24} alkynyl.

16. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from unsubstituted C_{10}-C_{18} alkyl, unsubstituted C_{10}-C_{18} alkenyl and unsubstituted C_{10}-C_{18} alkynyl.

17. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from unsubstituted C_{14} alkyl, unsubstituted C_{14} alkenyl and unsubstituted C_{14} alkynyl.

18. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a hydrocarbon chain.

19. (currently amended)A compound according to ~~any one of the preceding claims~~ claim 1 wherein Y is selected from S and Se.

20. (original) A compound according to claim 19 wherein Y is S.

21. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Z is an alkyl group.

22. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Z is a C_1-C_{10}, preferably C_1-C_6, preferably C_1-C_3 alkyl group.

23. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Z is $-CH_2-$.

24. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Y-Z together represent the group
$[Y^1\text{-}CH_2]_n$
wherein Y^1 is selected from S, Se, SO_2, SO, O, CH_2, wherein when Y^1 is CH_2, the chain X-Y-Z contains an even number of atoms, and wherein n is an integer from 1 to 20

25. (original) A compound according to claim 24 wherein Y^1 is selected from S, Se, SO_2, SO, and O.

26. (original) A compound according to claim 25 wherein Y^1 is selected from S and Se.

27. (original) A compound according to claim 26 wherein Y^1 is S.

28. (currently amended) A compound according to ~~any one of claims 24 to 26~~ claim 24 wherein n is from 1 to 10~~, preferably from 1 to 5, preferably 1, 2 or 3~~.

29. (currently amended) A compound according to ~~any one of claims 24 to27~~ claim 24 wherein n is 1.

30. (original) A compound according to claim 1 wherein the compound is of the formula



wherein Y^2 and Y^3 are independently S or Se, and X^2 and X^3 are independently selected from unsubstituted C_{10}-C_{18} alkyl, unsubstituted C_{10}-C_{18} alkenyl and unsubstituted C_{10}-C_{18} alkynyl.

31. (original) A compound according to claim 1 wherein the compound is of the formula



X^2 and X^3 are independently selected from unsubstituted C_{10}-C_{18} alkyl, unsubstituted C_{10}-C_{18} alkenyl and unsubstituted C_{10}-C_{18} alkynyl.

32. (original) A compound according to claim 1 wherein the compound is of the formula



X^2 and X^3 are independently selected from unsubstituted C_{14} alkyl, unsubstituted C_{14} alkenyl and unsubstituted C_{14} alkynyl.

33. (original) A compound according to claim 1 wherein the compound is of the formula



X^2 and X^3 are independently selected from $CH_3(CH_2)_{13}$-, $CH_3(CH_2)_6CH=CH(CH_2)_5$-, and $CH_3CH_2C\equiv C(CH_2)_{10}$-.

34. (original) A compound according to claim 30, 31, 32 or 33 wherein the polar head group is derived from the polar head group of a phospholipid.

35. (original) A compound according to claim 34 wherein the phospholipid is a phosphatidylcholine (PC) or a phosphatidylethanolamine (PE).

36. (original) A compound according to claim 1 wherein the compound is of the formula



wherein each W, X, Y and Z is selected independently of each other.

37. (original) A compound according to claim 36 wherein the compound is of the formula



wherein Y^2, Y^3 and Y^4 are independently S or Se, and X^2, X^3 and X^4 are independently selected from C_{10}-C_{18} alkyl, C_{10}-C_{18} alkenyl and C_{10}-C_{18} alkynyl.

38. (original) A compound according to claim 36 wherein the compound is of the formula



wherein X^2, X^3 and X^4 are independently selected from C_{10}-C_{18} alkyl, C_{10}-C_{18} alkenyl and C_{10}-C_{18} alkynyl.

39. (currently amended) A ~~combination~~ composition comprising a liposome and a compound according to ~~any one of claims 1 to 38~~ claim 1.

40. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 38 or a combination according to claim 39 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant~~ claim 1 or claim 39.

41. (original) A topically administrable pharmaceutical composition according to claim 40.

42. (original) A parenterally administrable pharmaceutical composition according to claim 40.

43. (original) An intravenously administrable pharmaceutical composition according to claim 42.

44. (canceled)

45. (currently amended) ~~Use of a compound according to any one of claims 1 to 38 claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment and/or prevention of~~ A method of treating or preventing a condition selected from syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

46. (currently amended) ~~Use of a compound according to any one of claims 1 to 38 claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~ A method of lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low

density lipoprotein, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

47. (currently amended) A method for producing ~~weigh~~ weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

48. (currently amended) A method for the modification of the fat distribution and content of animals, comprising administering to a subject in need thereof ~~thereto~~ an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

49. (currently amended) ~~Use of a compound according to any one of claims 1 to 38 claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition and/or prevention of~~ A method of inhibiting or preventing the growth of tumours, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

50. (currently amended) A method for the treatment ~~and/or~~ or inhibition of primary and secondary metastatic neoplasms, comprising administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

51. (currently amended) ~~Use of a compound according to any one of claims 1 to 38 claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~ A method for the prevention ~~and/or~~ or treatment of proliferative skin disorders, comprising administering to a subject in need thereof an effective

amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

52. (currently amended) ~~Use of a compound according to any one of claims 1 to 38~~ claim 1 ~~or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~ A method for the inhibition of proliferation ~~and/or~~ or induction of differentiation of keratinocytes, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

53. (currently amended) ~~Use of a compound according to any one of claims 1 to 38~~ claim 1 ~~or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~ A method for the prevention ~~and/or~~ or treatment of inflammatory disorders, comprising administering to a subject in need thereof and effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

54. (currently amended) A method for enhancing the endogenous production of interleukin-10 (IL-10) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

55. (currently amended) A method for suppression of the endogenous production of interleukin-2 (IL-2) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

56. (currently amended) ~~Use of a compound according to any one of claims 1 to 38~~ claim 1 ~~or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~ A method for the inhibition of proliferation of stimulated peripheral

mononuclear cells (PBMC), comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

57. (new) A pharmaceutical composition according to claim 40, admixed with a pharmaceutically carrier, diluent, excipient or adjuvant.

58. (new) A topically administrable pharmaceutical composition according to claim 57.

59. (new) A parenterally administrable pharmaceutical composition according to claim 57.

60. (new) An intravenously administrable pharmaceutical composition according to claim 57.